Main Index --- Treatments Index --- Circulars Index
COMPASSION RESPONSE NETWORK CIRCULAR No 21
Compassion Response Network has a policy objective of sponsoring a comparative survey of examining the results from at least nine alternative treatments for HIV/AIDS. Each treatment is provided for six months, and comprehensive blood tests and medical examinations are conducted at the pre-treatment stage and 2, 4, and 6 months after commencement of the treatment. Strict scientific-medical guidelines are adopted, and following each trial of a treatment, we publish the results in our CRN circular and on our CRN website. In this way, the general public will be able to examine the results for each treatment and come to a personal assessment of which treatments are effective in various ways in the fighting of HIV/AIDS. We are not aware of any other independent organisation publishing such a comparative survey of alternative treatments for HIV/AIDS.
CRN launched our global appeal to raise funds for the comparative survey in April 2003. Because of the limited response to that appeal, we were forced to trial just one treatment at a time on a shoe-string budget. The first treatment was trialled in Kinshasa, Democratic Republic of Congo, in 2003/2004; it was Imusil, a silver tetroxide compound with remarkable claims for healing HIV/AIDS. One of the three selected patients dropped out before the trial commenced, and so only two completed the six-months trial period. There was considerable improvement in health during the first two months, but neither patient showed a decline in HIV count or increase in CD4 immunity cell count over the trial period. The results are published on our CRN website.
Following the completion and publication of the Imusil results, our Inner Planning Circle adopted projects for trialling pure colloidal silver + oxyrich on three patients in Kinshasa, Democratic Republic of Congo, and for one patient using glyconutritional supplements in Dar-es-Salaam, Tanzania.
The budget estimates for the pure colloidal silver + oxyrich project was presented in CRN circular No 20 at A$7,000 = US$5,250, and this has recently been amended to A$7,447 = US$5,585, to include previously unforeseen expenses relating to taxi, nurse and clinic hire at the commencement of the treatment.
The budget estimates for the glyconutritionals project was also presented in CRN circular No 20, at A$2,280 = US$1,710, and this has recently been amended to A$2,580 = US$1,935, to include costs for pre-treatment blood tests, because an arrangement for independent sponsorship of these tests has not eventuated.
Overall, therefore, CRN was faced with money to raise totalling A$10,027 = US$7,520 to fund both projects. CRN has only just recently raised sufficient money to enable both projects to commence over the past month.
On 20/May/05, the Inner Planning Circle for CRN agreed on an initial budget of A$7,000 to sponsor trialling of a comparative treatment using pure colloidal silver plus oxyrich on three advanced HIV/AIDS patients over 6 months. The three advanced HIV/AIDS patients were selected and had their preliminary blood tests (bDNA + CD4 + FBC) taken by mid June.
Fundraising was difficult, but at last a generous commitment by an Australian lady to regularly donate A$500 a month permitted the project to proceed, and on 19/August/05, a package containing the pure colloidal silver + oxyrich plus other essential items was sent by private courier from Perth in Australia to Kinshasa, arriving in Kinshasa a week later.
Albert Mananga is our coworker in Kinshasa responsible for facilitating and overseeing the project. There was much preparatory work to be completed in Kinshasa, checking the contents of the package sent from Perth, reviewing notes on colloidal silver + oxyrich and translating them to French, and other blood tests had to be completed. Each patient would be taking the treatment daily at their home, and so the patients and a carer for each patient needed to be carefully instructed in how to take care of and take the daily treatment, and in understanding the special responsibilities to satisfy the requirements of the trial.
In the three months since the selection of the patients, their health had steadily deteriorated, especially one of them (patient A). It was decided to bring them to the clinic for final pre-treatment blood testing and by 22/September all three had commenced their treatment, supervised for the first two days. Because of their weak condition, they were offered a night’s care at the clinic supervised by a nurse before returning home. They would now take the treatment each morning upon arising, assisted by their home carer. Daily treatment would be 5 mls of pure colloidal silver (two eye dropper full tubes placed sub-lingually under the tongue, and held for a minute before swallowing. Soon after, each would take 2 mls of oxyrich (24 drops), in a drink of water.
Results during the first two weeks of treatment with pure colloidal silver + oxyrich.
These are early and unofficial observations. More definitive results must await the 2-monthly blood tests and comprehensive medical examination.
Patient A
Patient A is a 50-year old man, whose illness commenced in 1997. He had lost his wife, probably through AIDS, and had been on AZT treatment (which he has now stopped taking).
He was terminal in extent of his illness, and before pure colloidal silver treatment he was waiting for his death. He was very weak, too weak to walk, unable to eat solid food and he was close to passing away. Since pure colloidal silver treatment, all these symptoms have improved. He expresses now an eagerness to openly testify about the positive return of his health.
He previously had fevers, but these have now gone.
He has had a cough, suppressed through taking a product. After commencing treatment with pure colloidal silver plus oxyrich, he stopped taking this product and the cough has returned, it may be a purification process.
Candidose symptoms have disappeared since commencing treatment.
In the first two days after commencing treatment he experienced itchiness in the eyes, with a white substance eliminated from the eyes. The itchiness has since stopped.
A tickle or slight pain in the bones has been noticed since commencement of treatment.
While on AZT, he had a problem of pain in the big left toe and blockage of knees, causing difficulty in walking. Since taking colloidal silver the problem has stopped and he now enjoys walking.
He requires regular rest now.
Before he had regular diarrhea. Now the stools have become regular and normal.
His weight has remained at the same since treatment commenced.
Before pure colloidal silver treatment he was unable to eat solid foods. Now his appetite has returned, and he eats regularly again.
Patient B
Patient B is a 57 year old woman, whose illness began in 2002. Her treating doctor had hidden the diagnosis of AIDS from her, suggesting she had malaria or typhoid. Recent blood tests have confirmed her HIV infection. She was living by the coast and had recently moved to Kinshasa for treatment and care with family. Her symptoms are generally similar to those of patient A, but are not so extreme, although in the few days before receiving the pure colloidal silver treatment, she had a fever and a serious crisis.
Fevers, candidose and diarrhea, all problems before the pure colloidal silver treatment, have now all stopped. Her sleep is again normal.
She continued for a while to have pains in legs, but these pains have now disappeared. She is unable to lift heavy things and continues to express tiredness for which she needs much rest. She continues to have periods of dizziness.
Before colloidal silver treatment, she had lost her appetite and had much difficulty in feeding herself. She was aware of the approach of death. Since treatment began, she commenced properly feeding herself with fruits and soups. Now her appetite has fully returned, and she eagerly eats solid foods. This transformation in her appetite and feeding has given joy to her family.
Her family are delighted with her positive trend towards good health in all areas.
Patient C
Patient C is a 43 year old woman, who first became ill in 2001. Though she has tested as infected with HIV, she has been the least affected of the three patients. Her main symptoms related to rashes and itches, for which she had taken antibiotics (now she has stopped taking these)
She also had fevers, diarrhea, and headaches, but since commencing the taking of pure colloidal silver, her general health has improved.
She went into a deep-sleep at the commencement of the pure colloidal silver treatment, but she has now adjusted and again sleeps well.
In late April/05 our coworker in Tanzania, Shadrack Kavalambi, advised that his 36 year old nephew Bennett is seriously ill with advanced AIDS. His recent CD4 (immunity level) reading was just 8. Normal is about 500 and anything below 200 is dangerous as it allows infectious diseases to run havoc. A level of 8 is almost unheard of and exceedingly dangerous and close to death.
We then were committed to funding a trial in Kinshasa involving three patients, and we would not be able to sponsor any other project until the funding for the Kinshasa project was on track. And yet Shadrack had been such a dedicated and caring coworker. Over the past year we had discussed funding a project in Tanzania using a glyconutritionals treatment, a nutritional supplement with substantial claim for being a positive treatment for HIV/AIDS.
Shadrack clearly had such a strong affection for Bennett. But with our first funding priority being with the Kinshasa project, and very little response coming for that project, funding for a second project seemed out of the question. As Bennett seemed to then have a life expectancy of just a few weeks, what could we do?
And yet the Christ had said, that whatsoever shall be asked in Christ’s name and with faith in the response, will see it accomplished.
And so our prayer group asked, in simple faith that somehow a miracle would happen. Many of our coworkers would daily link into Bennett in prayer and meditation, affirming that we would find a pathway towards curing him of HIV/AIDS.
In May a private sponsor in Australia purchased sufficient glyconutritional tablets to treat Bennett for six months. They were consecrated for use in an alternative treatments trial. The intention was to send the tablets over to Tanzania by private courier, but on condition that they be used only if the funding for the entire six months of a scientific/medical trial seemed likely to be successful. The glyconutritional tablets arrived at CRN head office in Perth on 20/May/05.
Again through an answer to prayer, a private donation permitted these tablets to be courier delivered to Dar-es-Salaam, Tanzania, arriving on 16/June.
The treatment is by way of three types of tablets, Ambrotose AO, Plus and Catalyst, taken each day. The treatment is essentially a nutritional supplement. It has good reports of positive results with HIV/AIDS patients. Our intention is to do a complete 6-months testing trial with Bennett to provide a one-person trial to commence our own assessment of its value.
By this time, we had attracted a sponsor in Australia committing to donate A$500 a month until the Kinshasa pure colloidal silver + oxyrich project had been completed. We were three quarters covered for our needed funding. We received an expression of interest from within Tanzania to fund the pre-treatment blood tests for the trial (costing US$183). We committed that if these pre-treatment tests were completely sponsored, CRN would fund the remaining costs, amounting to over US$1,400.
The first regular payment for commencement of the Kinshasa project was sent in mid September, and we would be able to send a first payment to Dar-es-Salaam by mid October. In the meantime, the promised local funding of the pre-treatment blood tests did not eventuate, and so CRN committed to pay for this cost as well. But the pre-treatment tests could not now be arranged until after the October payment had been received.
A further problem arose when for six weeks from mid-August, we had lost email contact with our coworker Shadrack. We continued to pray in faith. It turned out that Shadrack had suffered severe head injuries during a car accident, and had been unable to make email contact. On 30/September however, Shadrack renewed contact and advised that his head injuries had sufficiently recovered. And amazingly, Bennett was still surviving, though his condition had deteriorated over the several months of waiting. He had developed painful boils on his legs, and by now he was so weak he could hardly walk. His appetite remained fair however.
Within a week, CRN was for the first time in a position to send money over to Tanzania, sufficient to sponsor the required pre-treatment blood tests and the first two months of the trial. CRN had received a much needed donation of A$500 above previously committed amounts, just sufficient for us to send the required money over to Tanzania.
Shadrack went into immediate action to finalise preparations for the treatment. Blood tests were taken on Monday 10/October. A doctor, nurse and nurse administrator were found to support the project. Comprehensive case study documents needed to be filled out. Bennett’s condition continued to deteriorate. He no longer had the strength to walk, and he had to be moved in a wheelchair. It seemed he was hanging onto life by a thread. He developed a fever for which antibiotics were prescribed. His emotional will to live had revived once he was told that the CRN funding had arrived.
Shadrack reported that Bennett received his pre-treatment comprehensive medical examination on Sunday, 16/October/05. Treatment with glyconutritionals began that evening. The last report received from Shadrack before the writing of this CRN circular, was received four days later, on 20/October.
Bennett reported that his body pains had disappeared. Part of his left foot that had been swollen, was now back to normal. His movements are stabilised. The itchiness in various parts of the body that he had been experiencing were gone. He was still having diarrhea. He was confident and joyful in his dramatic improvement in general health.
Bennett had been taking ARV drugs for 5 years to try to counter the AIDS. He has now stopped taking these, but perhaps they may have contributed substantial body toxicity which now needs to be eliminated.
Compassion Response Network is a registered company with charitable objectives. A yearly audit of our accounts requires that funds be used exclusively for the charitable objectives. Our purpose is to assist the public in sponsoring and funding alternative treatments for HIV/AIDS, with a view of discovering in a comparative survey those treatments that seem likely to cure HIV/AIDS.
To fund the two projects, one in Kinshasa and the other in Dar-es-Salaam, will require the raising of a total of A$10,027 = US$7,520. To the present date, adding together donations so far received and commitments for donations over the next six months, CRN is able to reach over 80% of this target.
But CRN still lacks A$1,860 to reach the full target. A$500 of this needs to be raised from the general public (apart from committed contributions) by mid November. The remainder needs to be raised by mid March 2006. The Australian lady who presently is donating A$500 a month, is making that commitment on condition that her part time employment continues until April 2006. She however has a concern that she may be forced to retire early. If that were to happen, then the amount CRN must raise will be increased by A$500 extra for each month of her early retirement. We appeal strongly to the general public to help raise the urgently needed money. Without such funding the continuation of the projects in Kinshasa and Dar-es-Salaam could be in jeopardy.
The longer term goal is for CRN to raise sufficient funds to trial nine alternative treatments for HIV/AIDS, three advanced HIV/AIDS patients for each treatment. During 2003/2004 CRN sponsored the trial of two patients using Imusil as the selected treatment. Now CRN has commenced treatment of four more patients, three using pure colloidal silver + oxyrich, and one using glyconutritional supplements. This will bring to completion the trialling of six patients in all, compared with our eventual goal of 27 patients for the complete comparative survey.
Why has no other group previously undertaken such a comparative survey using state of the art medical scientific tests? Is it not clear that the ONLY way for the general public to gain confidence in which alternative treatments for HIV/AIDS live up to their often strong claims of having curative properties, is that a comparative trial needs to be conducted by an independent, neutral, international charitable body?
Then why has no group accepted this challenge before? Why is the flow of donations to CRN so meager except for the contributions of a few who can be counted on the fingers of one hand and sacrifice to the limit in order to donate? After all, the discovery of a safe, effective, cheap alternative treatment cure for HIV/AIDS will affect and give hope to millions around the globe. Why is it taking so long to fund CRN projects? How many more years will pass, and how many millions of people will die from AIDS before CRN receives sufficient funding to (even on shoe string budgets) fund the trialling of in all 27 patients with HIV/AIDS?
Shadrack has mentioned that Bennett has a sister who also has HIV/AIDS. If the present funding trends towards CRN were to continue, Bennett’s treatment of six months will be completed before further funds will be raised for trialling further patients and more alternative treatments. By that time, Bennett’s sister would most probably have passed away.
Over the next year, CRN seeks to fund at least three more advanced HIV/AIDS trials two with glyconutritionals, and one more with Imusil. Then we would have completed the trials for three patients on each of three treatments.
If today CRN was to receive a further commitment for a regular monthly donation of A$500 = US$370, then once our November payments are covered, this would then permit an immediate acceptance of one more glyconutionals patient in Tanzania, and acceptance of a second glyconutritionals patient when there is sufficient savings. A$500 a month would be a big sacrifice, but how much more would most people living in affluent countries be prepared to sacrifice if they or a close member of their family had a terminal illness?
The purpose and goal of CRN is to assist those who choose to make such meaningful contributions and sacrifices, for the benefit of all humanity. Upon such charity, lies the future hope of the millions in Africa and around the world with HIV/AIDS.
Yours with love and light,
David Keane,
Secretary, Compassion Response Network.